2- and 8-alkynyladenosines: Conformational studies and docking to human adenosine A3 receptor can explain their different biological behavior

Journal of Molecular Graphics and Modelling

Volumn 21, Issue 4, 2003, Pages 253-262

  Costanzi, Stefano ^a   Lambertucci, Catia ^a   Vittori, Sauro ^a   Volpini, Rosaria ^a   Cristalli, Gloria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Adenosine receptors; Conformational analysis; Docking; GPCR; Homology modeling; NMR

Indexed keywords

CONFORMATIONS; DERIVATIVES; NITROGEN COMPOUNDS; NUCLEAR MAGNETIC RESONANCE; X RAY ANALYSIS;

BINDING SITES;

MOLECULAR STRUCTURE;

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ALKYNYL GROUP; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); RHODOPSIN;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; HUMAN; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ADENOSINE; AMINO ACID SEQUENCE; ANIMALS; CATTLE; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ADENOSINE A3; RHODOPSIN; SEQUENCE ALIGNMENT;

BOVINAE;

EID: 0037212478     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1093-3263(02)00161-4     Document Type: Article

References (42)

1. G.L. Stiles, Adenosine receptor subtypes: New insights from cloning and functional studies, in: K.A. Jacobson, M.F. Jarvis (Eds.), Purinergic Approaches in Experimental Therapeutics, Wiley-Liss, New York, 1997, pp. 29-37.
2. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492.
3. Horn F., Vriend G., Cohen F.E. Collecting and harvesting biological data: the GPCRDB & NucleaRDB databases. Nucl. Acids Res. 29:2001;346-349.
4. Meyerhof W., Muller-Brechlin R., Richter D. Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. FEBS Lett. 284:1991;155-160.
5. Zhou Q.Y., Li C., Olah M.E., Johnson R.A., Stiles G.L., Civelli O. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl. Acad. Sci. U.S.A. 89:1992;7432-7436.
6. Sajjadi F.G., Firestein G.S. cDNA cloning and sequence analysis of the human A3 adenosine receptor. Biochim. Biophys. Acta. 1179:1993;105-107.
7. Salvatore C.A., Jacobson M.A., Taylor H.E., Linden J., Johnson R.G. Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10365-10369.
8. Palmer T.M., Stiles G.L. Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat A(3) adenosine receptor. Mol. Pharmacol. 57:2000;539-545.
9. Chen A., Gao Z.G., Barak D., Liang B.T., Jacobson K.A. Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis. Biochem. Biophys. Res. Commun. 284:2001;596-601.
10. Jacobson K.A., Gao Z.G., Chen A., Barak D., Kim S.A., Lee K., Link A., Rompaey P.V., van Calenbergh S., Liang B.T. Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. J. Med. Chem. 44:2001;4125-4136.
11. Liang B.T., Jacobson K.A. Adenosine and ischemic preconditioning. Curr. Pharm. Des. 5:1999;1029-1041.
12. Stambaugh K., Jacobson K.A., Jiang J.L., Liang B.T. A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia. Am. J. Physiol. 273:1997;H501-H505.
13. Liang B.T., Jacobson K.A. A physiological role of the adenosine A3 receptor: sustained cardioprotection. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6995-6999.
14. Von Lubitz D.K., Lin R.C., Boyd M., Bischofberger N., Jacobson K.A. Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur. J. Pharmacol. 367:1999;157-163.
15. Jacobson K.A., Von Lubitz D.K., Daly J.W., Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17:1996;108-113.
16. 2B ligands. J. Med. Chem. 45:2002;3271-3279.
17. Volpini R., Costanzi S., Lambertucci C., Vittori S., Klotz K., Lorenzen A., Cristalli G. Introduction of alkynyl chains on C8 of adenosine led to very selective antagonists of the A(3) adenosine receptor. Bioorg. Med. Chem. Lett. 11:2001;1931-1934.
18. Stolarski R., Dudycz L., Shugar D. NMR studies in the syn-anti dynamic equilibrium in purine nucleosides and nucleotides. Eur. J. Biochem. 108:1980;111-121.
19. 1H NMR study of the syn-anti dynamic equilibrium in adenine nucleosides and nucleotides with the aid of some synthetic model analogues with fixed conformations. Z. Naturforsch. [C]. 34C:1979;359-373.
20. HyperChem, Version 6.03, Hypercube Inc., Gainesville, FL, USA, 2000.
21. Dewar M.J.S., Zoebisch E.G., Healy E.F., Stewart J.J.P. AM1: a new general purpose quantum mechanical model. J. Am. Chem. Soc. 107:1985;3902-3909.
22. Allinger N.L. Conformational analysis 130.MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J. Am. Chem. Soc. 99:1977;8127-8134.
23. Guex N., Peitsch M.C. SWISS-MODEL and the SwissPdbViewer: An environment for comparative protein modeling. Electrophoresis. 18:1997;2714-2723.
24. SwissPdb, Version 3.7 (Beta 2), GlaxoSmithKline R&D, Geneva, Swiss, 2000 ( http://www.expasy.ch/spdbv/ ).
25. Cornell W.D., Cieplak P., Bayly C.I., Gould I.R., Merz K.M. Jr., Ferguson D.M., Spellmeyer D.C., Fox T., Caldwell J.W., Kollman P.A. A second generation force field for the simulation of proteins nucleic acids, and organic molecules. J. Am. Chem. Soc. 117:1995;5179-5197.
26. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 289:2000;739-745.
27. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The Protein Data Bank. Nucl. Acids Res. 28:2000;235-242.
28. van Galen P.J.M., Ijzerman A.P., Soudijin W. Xanthine-7-ribosides as adenosine A1 receptor antagonists: further evidence for adenosine's anti mode of binding. Nucleosides Nucleotides. 9:1990;275-291.
29. Bruns R.F. Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can. J. Physiol. Pharmacol. 58:1980;673-691.
30. Kim J., Wess J., Van Rhee A.M., Schoneberg T., Jacobson K.A. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J. Biol. Chem. 270:1995;13987-13997.
31. Barbhaiya H., McClain R., Ijzerman A., Rivkees S.A. Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Mol. Pharmacol. 50:1996;1635-1642.
32. Scholl D.J., Wells J.N. Serine and alanine mutagenesis of the nine native cysteine residues of the human A(1) adenosine receptor. Biochem. Pharmacol. 60:2000;1647-1654.
33. Rivkees S.A., Barbhaiya H., Ijzerman A.P. Identification of the adenine binding site of the human A1 adenosine receptor. J. Biol. Chem. 274:1999;3617-3621.
34. Townsend-Nicholson A., Schofield P.R. A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. J. Biol. Chem. 269:1994;2373-2376.
35. Dalpiaz A., Townsend-Nicholson A., Beukers M.W., Schofield P.R., Ijzerman A.P. Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. Biochem. Pharmacol. 56:1998;1437-1445.
36. Gao Z.G., Jiang Q., Jacobson K.A., Ijzerman A.P. Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. Biochem. Pharmacol. 60:2000;661-668.
37. Ijzerman A.P., Von Frijtag Drabbe Künzel J.K., Kim J., Jiang Q., Jacobson K.A. Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition. Eur. J. Pharmacol. 310:1996;269-272.
38. Jiang Q., Lee B.X., Glashofer M., Van Rhee A.M., Jacobson K.A. Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J. Med. Chem. 40:1997;2588-2595.
39. Jiang Q., Van Rhee A.M., Kim J., Yehle S., Wess J., Jacobson K.A. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol. Pharmacol. 50:1996;512-521.
40. van der Wenden E.M., Von Frijtag Drabbe Künzel J.K., Mathot R.A., Danhof M., Ijzerman A.P., Soudijn W. Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor. J. Med. Chem. 38:1995;4000-4006.
41. 1 receptor antagonists. J. Med. Chem. 40:1997;3765-3772.
42. Vittori S., Lorenzen A., Stannek C., Costanzi S., Volpini R., Ijzerman A.P., Von Frijtag Drabbe Künzel J.K., Cristalli G. N-Cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor. J. Med. Chem. 43:2000;250-260.